Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Marisa Rose Nucci, M.D.

Co-Author

This page shows the publications co-authored by Marisa Nucci and Esther Oliva.
Connection Strength

1.470
  1. Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade). Int J Gynecol Pathol. 2019 Jan; 38 Suppl 1:S93-S113.
    View in: PubMed
    Score: 0.206
  2. Alveolar Soft Part Sarcoma of the Female Genital Tract: A Morphologic, Immunohistochemical, and Molecular Cytogenetic Study of 10 Cases With Emphasis on its Distinction From Morphologic Mimics. Am J Surg Pathol. 2017 May; 41(5):622-632.
    View in: PubMed
    Score: 0.183
  3. Frequent expression of KIT in endometrial stromal sarcoma with YWHAE genetic rearrangement. Mod Pathol. 2014 May; 27(5):751-7.
    View in: PubMed
    Score: 0.144
  4. Intestinal-type endocervical adenocarcinoma in situ: an immunophenotypically distinct subset of AIS affecting older women. Am J Surg Pathol. 2013 May; 37(5):625-33.
    View in: PubMed
    Score: 0.139
  5. Interobserver variability in the interpretation of tumor cell necrosis in uterine leiomyosarcoma. Am J Surg Pathol. 2013 May; 37(5):650-8.
    View in: PubMed
    Score: 0.139
  6. Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. Am J Surg Pathol. 2012 Oct; 36(10):1562-70.
    View in: PubMed
    Score: 0.134
  7. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol. 2012 May; 36(5):641-53.
    View in: PubMed
    Score: 0.130
  8. International Endocervical Adenocarcinoma Criteria and Classification: Validation and Interobserver Reproducibility. Am J Surg Pathol. 2019 01; 43(1):75-83.
    View in: PubMed
    Score: 0.051
  9. Interobserver Reproducibility Among Gynecologic Pathologists in Diagnosing Heterologous Osteosarcomatous Component in Gynecologic Tract Carcinosarcomas. Int J Gynecol Pathol. 2017 Jul; 36(4):386-392.
    View in: PubMed
    Score: 0.046
  10. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. J Pathol. 2016 Feb; 238(3):389-400.
    View in: PubMed
    Score: 0.042
  11. GATA3 Is a Sensitive and Specific Marker of Benign and Malignant Mesonephric Lesions in the Lower Female Genital Tract. Am J Surg Pathol. 2015 Oct; 39(10):1411-9.
    View in: PubMed
    Score: 0.041
  12. Significance of lymphovascular space invasion in uterine serous carcinoma: what matters more; extent or presence? Int J Gynecol Pathol. 2015 Jan; 34(1):47-56.
    View in: PubMed
    Score: 0.039
  13. Is the two-tier ovarian serous carcinoma grading system potentially useful in stratifying uterine serous carcinoma? A large multi-institutional analysis. Gynecol Oncol. 2014 Feb; 132(2):372-6.
    View in: PubMed
    Score: 0.036
  14. Interobserver agreement for assessing invasion in stage 1A vulvar squamous cell carcinoma. Am J Surg Pathol. 2013 Sep; 37(9):1336-41.
    View in: PubMed
    Score: 0.036
  15. Histotype-genotype correlation in 36 high-grade endometrial carcinomas. Am J Surg Pathol. 2013 Sep; 37(9):1421-32.
    View in: PubMed
    Score: 0.036
  16. Clinical and pathologic characteristics of serous carcinoma confined to the endometrium: a multi-institutional study. Int J Gynecol Pathol. 2013 Mar; 32(2):181-7.
    View in: PubMed
    Score: 0.034
  17. Correlation of tumor size with other prognostic factors in uterine serous carcinoma: a large multi-institutional study. Gynecol Oncol. 2013 Feb; 128(2):316-21.
    View in: PubMed
    Score: 0.034
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.